Conférences  >  Médecine & Soins de Santé  >  Pharmacologie et développement des médicaments  >  Chine

European Society for Medical Oncology

ESMO TAT, the multi-stakeholder forum gathering key actors in cancer drug development, arrives in one of the most dynamic and best-connected hubs in Asia, making the latest advances in early clinical trials accessible to everyone in the region. Through in-depth discussions on critical topics such as innovation, digital transformation, research methodology, business insights, regulation, and public policy, ESMO TAT Asia aims to drive progress in cancer treatment and research. Located in the lively city of Hong Kong, ESMO TAT Asia promises to be a vibrant gathering with region’s industry, academia, clinicians, and regulators to promote international cooperation and accelerate the anticancer research. Come and join us to chart new paths in cancer drug development in Asia.

ESMO Asia TAT 2025 Secretariat;     Email.: asiacongress@esmo.org

targeted therapies, early drug development, cancer therapeutics, immunotherapy, cytotoxic therapy, cell therapy, biotech, pharmaceutical industry

World High Technology Society

The Annual Congress of International Drug Discovery Science & Technology (IDDST), initiated from 2003, has been successfully organized in Shanghai (China), Beijing (China), Shenzhen (China), Nanjing (China), Haikou (China), Suzhou (China), Xi’an (China), Gyeonggi (South Korea), Osaka (Japan), Boston (USA), Kyoto (Japan), Tokyo (Japan), Amsterdam (the Netherlands), Osaka (Japan) and Budapest (Hungary) and has attracted more than 10000 participants from over 50 countries and regions in the previous 20 years. The 21th IDDST (Europe) will be held during June 18-20, 2025 at Stockholm, Sweden. It continues to expand with magnificent scientific and social programs to maximize your network in a free communication meeting environment.

The 21th IDDST (Europe) will host leading scientists from the academia and industry worldwide, to discuss the latest developments in drug discovery and therapy. The program of the coming conference promises to be very interesting for both basic scientists and executives who are working in the field of drug discovery and other related areas, they will offer complete updates of recent developments and present the latest results in the remarkable separate tracks. With the participation of outstanding international experts, we hope productive discussions would stimulate new creative ideas to translate new discoveries into better practice and application.